Canada Markets open in 1 hr 40 mins

Defence Therapeutics Inc. (DTCFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.94000.0000 (0.00%)
At close: 10:12AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close3.9400
Open4.3880
BidN/A x N/A
AskN/A x N/A
Day's Range4.0300 - 4.3880
52 Week Range2.5000 - 6.4078
Volume8
Avg. Volume1,231
Market Cap141.701M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Defence's Accum(TM)-HPV Vaccine Formulation (AccuVAC-PT009) Activates a 36-Fold Higher Humoral Response Compared to Gardasil-9

    Vancouver, British Columbia--(Newsfile Corp. - January 26, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the development of AccuVAC-PT009, a new protein-based HPV vaccine, leading to a humoral response bypassing Gardasil-9 (Merck) immunogenicity in animals.ACCUMTM is a platform technology 100% owned by Defence Therapeutics. ACCUMTM is

  • Newsfile

    Defence Therapeutics Achieves a Major Milestone and Begins IND-Enabling Testing of Its AccuTOX Lead Compound Against Breast Cancer

    Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the start of its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited prior to initiate its Phase I trial in breast cancer patients. Eurofins Advinus Limited is a leading Drug Discovery ..

  • Newsfile

    Defence Therapeutics Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of the CRISPR/Cas9 Protein to Target Cells

    Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company focused on the development of vaccines and therapeutics against cancer and infectious diseases, is pleased to announce that its AccumTM platform can potently enhance Cas9 delivery in target cells, which would have a significant positive impact on the CRISPR industry. The CRISPR technology offers the potential t